Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of ABI-009 (Nab-Rapamycin) With Pazopanib (VOTRIENT) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas

Trial Profile

A Phase 1/2 Study of ABI-009 (Nab-Rapamycin) With Pazopanib (VOTRIENT) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Pazopanib (Primary) ; Sirolimus (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2019 Planned initiation date changed from 25 Jan 2019 to 1 Apr 2019.
    • 15 Nov 2018 Planned initiation date changed from 25 Oct 2018 to 25 Jan 2019.
    • 12 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top